Compare Extra Space Storage, Inc. (EXR) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Extra Space Storage, Inc. trades at $146.41 (market cap $30.96B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Extra Space Storage, Inc. is far larger — about 394.1× Inovio Pharmaceuticals Inc's market cap, and Extra Space Storage, Inc. pays a 4.42% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| EXR | INO | |
|---|---|---|
Market Cap | $30.96B | $78.55M |
Sector | Real Estate | Health |
52-Week High | $152.85 | $2.87 |
52-Week Low | $126.67 | $0.66 |
Enterprise Value | $44.68B | $49.56M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXR trades at $146.77, up 0.08% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating FFO estimates, and maintains robust fundamentals with a 27.79% net income margin. Recent news highlights a 52-week high of $155.80 reached in late July 2026, though the stock has since pulled back slightly.
The outlook is mixed; solid earnings growth and a secure 4.3% dividend yield support the bull case, but high valuation multiples (P/E of 32.35) and increasing debt levels pose risks. Analyst consensus is a 'Hold' with a $157.25 price target, suggesting limited near-term upside from current levels amid competitive pressures.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
